Aggressive Lymphomas
News
Secondary CNS lymphoma regimen linked to 41% survival at 5 years
Key clinical point: High doses of antimetabolites followed by R-HDS and autologous stem-cell transplantation was feasible and effective in 38...
News
Lymph2Cx assay identifies outcomes in DLBCL
Key clinical point: The Lymph2Cx is an accurate assay for DLBCL cell of origin assignment, and identified groups with significantly different...
News
Less toxic chemo for HIV-positive Burkitt lymphoma
Key clinical point: A modified form of a standard chemotherapy regimen for Burkitt lymphoma is effective in HIV-positive patients, with lower...
News
Early follicular lymphoma progression signals poor outcomes
Key clinical point: Disease progression within 2 years of chemotherapy for follicular lymphoma is associated with poor outcomes. Major finding:...
News
Guideline updated on hematopoietic colony-stimulating factors
Conference Coverage
CUDC-907 passes early hurdle in heavily pretreated lymphoma, myeloma
Key clinical point: The dual HDAC and Pi3K inhibitor CUDC-907 was reasonably tolerated and clinically active in a phase I study of heavily...
News
ABVD and Stanford V similar for bulky mediastinal Hodgkin’s lymphoma
Key clinical point: No significant differences in outcomes were observed after treatment with ABVD vs. Stanford V in patients with stage I or II...
News
Brentuximab doubles PFS in Hodgkin’s lymphoma patients
News
Autologous stem-cell transplant boosts survival in sequential transformed indolent lymphoma
Key clinical point: Autologous stem-cell transplantation (ASCT) plus chemo improved responses for patients with sequential indolent lymphoma...
Conference Coverage
Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients
Key clinical point: Brentuximab vedotin given immediately post-transplant significantly improves progression-free survival in patients with...
Conference Coverage
PD-1 checkpoint inhibitors show mettle against relapsed Hodgkin’s lymphoma
Key clinical point: PD-1 checkpoint inhibition appears to be an effective strategy against treatment-refractory Hodgkin’s lymphoma. Major finding...